Macrosol (13.125 gm+350.7 mg+178.5 mg+46.6 mg)/25 ml (Oral Solution)

Indications

• Effective relief from constipation in adults and children over 12 years
• Treatment of chronic constipation
• Treatment of fecal impaction (refractory constipation with fecal loading)
• Relief from fecal impaction

Composition

• Polyethylene Glycol 3350: 13.125 gm in 25 ml concentrated oral solution
• Sodium Chloride: 350.7 mg in 25 ml concentrated oral solution
• Sodium Bicarbonate: 178.5 mg in 25 ml concentrated oral solution
• Potassium Chloride: 46.6 mg in 25 ml concentrated oral solution
• Polyethylene Glycol 3350: 13.125 gm in each sachet (powder for suspension)
• Sodium chloride: 350.7 mg in each sachet (powder for suspension)
• Sodium Bicarbonate: 178.5 mg in each sachet (powder for suspension)
• Potassium Chloride BP: 46.6 mg in each sachet (powder for suspension)

Pharmacology

• Osmotic action in the gut
• Laxative effect
• Increases stool volume
• Triggers colon motility
• Improved propulsive colonic transportation
• Facilitation of defecation
• Electrolyte exchange across the intestinal barrier
• Virtually unabsorbed from the gastrointestinal tract

Dosage & Administration

• Dose varies for constipation and fecal impaction
• Dilution instructions for oral solution
• Dosage adjustment for patients with renal insufficiency

Interaction

• Transient reduction in absorption of other medicinal products
• Possibility of decreased efficacy with some concomitantly administered medicinal products

Contraindications

• Intestinal perforation or obstruction
• Ileus
• Severe inflammatory conditions of the intestinal tract
• Toxic megacolon
• Hypersensitivity to the active substances

Side Effects

• Allergic reactions
• Electrolyte disturbances (hyperkalaemia, hypokalaemia)
• Abdominal pain
• Diarrhea
• Headache
• Peripheral edema

Pregnancy & Lactation

• No anticipated effects during pregnancy
• Safe for use during pregnancy
• Negligible systemic exposure to breastfed newborn/infant
• Safe for use during breastfeeding

Precautions & Warnings

• Dosage adjustments for patients with impaired cardiovascular function
• Monitoring for symptoms indicating fluid/electrolyte shifts
• Possible dependence with prolonged use

Overdose Effects

• Treatment for severe pain or distention
• Correction of electrolyte disturbances

Therapeutic Class

• Osmotic purgatives

Storage Conditions

• Store below 30°C
• Protect from light
• Do not refrigerate

Related Brands

• Movicol (13.125 gm+350.7 mg+178.5 mg+46.6 mg)/25 ml (Oral Solution) - mundipharma-bd-pvt-ltd